Market Overview

UPDATE: Morgan Stanley Reiterates On Amgen On New CFO

Related AMGN
Stocks Mixed Despite Better Than Expected GDP
Amgen Price Target Raised by Various Analysts
Yellen Swats Down Biotech, Social Media Stocks (Fox Business)

In a report published Tuesday, Morgan Stanley analyst Matthew Harrison reiterated an Overweight rating on Amgen (NASDAQ: AMGN), but removed the $140.00 price target.

In the report, Morgan Stanley noted, “David W. Meline, former CFO of 3M, appointed new CFO: Meline joins from 3M where he served as CFO for the last 3 years and corporate controller for the 3 years prior to CFO. Amgen has been without a permanent CFO since Jon Peacock stepped down on 1/10/2014.

"Multi-national and P&L management experience cited as key attributes: Amgen management cited Meline's experience as a divisional CFO at GM for Brazil, Europe and North American, plus his experience at 3M as CFO for a company with operations in 70 countries, as important experience he can bring to Amgen as it expands its international operations – a goal which remains a priority for management.

"Further, Meline understands how to run a cost efficient business – another key area that Amgen management cited as important to the CFO role.”

Amgen closed on Monday at $116.40.

Posted-In: Matthew Harrison Morgan StanleyAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (AMGN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional